☆ 4.7 Article

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

JOURNAL OF CLINICAL ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

Kevin J. Harrington et al.

Summary: The study presents a post hoc analysis of the long-term efficacy and progression-free survival in recurrent/metastatic head and neck squamous cell carcinoma patients treated with pembrolizumab and pembrolizumab-chemotherapy as next-line therapy. The results demonstrate favorable clinical efficacy and progression-free survival with pembrolizumab and pembrolizumab-chemotherapy in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) >= 20, CPS >= 1, and total populations. Subsequent treatments after pembrolizumab-based therapy also showed good efficacy.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Luis G. Paz-Ares et al.

Summary: Nivolumab plus ipilimumab continues to demonstrate durable long-term efficacy in patients with advanced NSCLC, with a significant improvement in overall survival compared to chemotherapy. Immune-mediated adverse events occur early but can be managed with guideline-based treatment. Discontinuation of nivolumab plus ipilimumab due to adverse events does not impact the long-term benefits seen in all randomized patients.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141

Maura L. Gillison et al.

Summary: Nivolumab has shown significant improvement in overall survival for patients with squamous cell carcinoma of the head and neck, particularly those who have failed platinum-based therapy. Long-term follow-up analysis confirms the sustained efficacy of nivolumab as a first-line treatment, with no new safety concerns identified.

ONCOLOGIST (2022)

添加到收藏夹

Article Medicine, General & Internal

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas et al.

Summary: Nivolumab plus ipilimumab demonstrated significant improvement in overall survival compared to standard chemotherapy for unresectable malignant pleural mesothelioma. This first-in-class treatment regimen has been approved for previously untreated patients in the USA and showed promising outcomes with manageable adverse events.

LANCET (2021)

添加到收藏夹

Article Pathology

Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer

Kenneth Emancipator et al.

Summary: Tumor proportion score (TPS) and combined positive score (CPS) are two methods used to evaluate PD-L1 expression, and CPS >= 50 appears to be equivalent to TPS >= 50% in predicting response rates. CPS may be more sensitive than TPS at lower cutoffs.

MODERN PATHOLOGY (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

Joel Guigay et al.

Summary: The aim of this study was to compare the efficacy and safety of the TPEx regimen with the standard of care EXTREME regimen in patients with recurrent or metastatic HNSCC. The results showed no significant difference in overall survival between the two regimens, but the TPEx regimen had a more favorable safety profile.

LANCET ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.

Ian Chau et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study

R. L. Ferris et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Head and neck squamous cell carcinoma

Daniel E. Johnson et al.

NATURE REVIEWS DISEASE PRIMERS (2020)

添加到收藏夹

Article Oncology

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

Laurence Albiges et al.

ESMO OPEN (2020)

添加到收藏夹

Article Oncology

Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

J-P Machiels et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Review Medicine, General & Internal

Head and Neck Cancer

Laura Q. M. Chow

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Robert Motzer et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

Maura L. Gillison et al.

ONCOLOGIST (2018)

添加到收藏夹

Article Oncology

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Robert L. Ferris et al.

ORAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Matthew D. Hellmann et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

R. L. Ferris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Review Oncology

The blockade of immune checkpoints in cancer immunotherapy

Drew M. Pardoll

NATURE REVIEWS CANCER (2012)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

Review Medicine, General & Internal

Head and neck cancer

Athanassios Argiris et al.

LANCET (2008)

添加到收藏夹

Article Medicine, General & Internal

Platinum-based chemotherapy plus cetuximab in head and neck cancer

Jan B. Vermorken et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

Article Health Care Sciences & Services

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer

A. Simon Pickard et al.

HEALTH AND QUALITY OF LIFE OUTCOMES (2007)

添加到收藏夹

Article Health Care Sciences & Services

A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores

Susan Yount et al.

QUALITY OF LIFE RESEARCH (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.